AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

NEURIZON THERAPEUTICS LTD

0.089

+0.0078.54%

Volume:241.84K

Turnover:21.15K

Market Cap:63.02M

PE:-3.01

High:0.090

Open:0.084

Low:0.084

Close:0.082

52wk High:0.185

52wk Low:0.075

Shares:708.13M

Float Shares:351.37M

Volume Ratio:1.07

T/O Rate:0.07%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.030

EPS(LYR):-0.034

ROE:-147.09%

ROA:-60.21%

PB:7.61

PE(LYR):-2.61

Loading ...

Overview Company News Filings

BUZZ-Australia's Neurizon Therapeutics drops to 2-year low on discounted placement

Neurizon Therapeutics Ltd - Firm Commitments to Raise a$7.1 Mln via Placement at a$0.08 per Share

THOMSON REUTERS

BRIEF-Neurizon Therapeutics Seeks Trading Halt

Neurizon Therapeutics - Seeks Trading Halt Pending Proposed Capital Raising Announcement

THOMSON REUTERS

ASX Penny Stocks To Consider In December 2025

Simply Wall St.

FDA Clears Nuz-001 for Entry Into Healey ALS Platform Trial

THOMSON REUTERS

Neurizon Says US FDA Clears Use of Drug Candidate in ALS Clinical Trial

MT Newswires Live

BUZZ-Australia's Neurizon Therapeutics jumps after US FDA clears ALS product for trial use

Neurizon Completes Manufacturing Three Registration Batches of Drug Candidate to Treat Neurodegenerative Disease; Shares Fall 5%

MT Newswires Live

Elanco Executive Justine Conway Appointed as Neurizon Therapeutics Board Observer

Elanco Executive Appointed as Neurizon's Board Observer

THOMSON REUTERS

Press Release: Elanco executive appointed as Neurizon's Board Observer

Neurizon Therapeutics Ltd-Appendix 4C & Quarterly Update

THOMSON REUTERS

Notice of Annual General Meeting & Proxy Form-GDR

Pre-Quotation Disclosure-GDR

Corporate Governance Statement-GDR

Top 20 Shareholders-GDR

Neurizon Therapeutics Ltd-Distribution Schedule-Gdr

THOMSON REUTERS

Distribution Schedule-GDR

Securities Trading Policy-GDR

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NUZ.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NUZ.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","market":"AU","secType":"STK","nameCN":"NEURIZON THERAPEUTICS LTD","latestPrice":0.089,"timestamp":1776233520000,"preClose":0.082,"halted":0,"volume":241840,"delay":0,"changeRate":0.0853658536585365,"nameEN":"NEURIZON THERAPEUTICS LTD","floatShares":351374969,"shares":708128681,"eps":-0.029543,"marketStatus":"Not Yet Opened","change":0.007,"latestTime":"04-15 16:12:00 AEST","open":0.084,"high":0.09,"low":0.084,"amount":21147,"amplitude":0.073171,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.029543,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1776297600000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.082,"openAndCloseTimeList":[[1776211200000,1776232800000]],"volumeRatio":1.0746772728063376,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"NUZ.AU","preClose":0.082,"auctionPrice":0.084,"auctionVolume":22500,"auction":3,"marketStatus":"盘后竞价","timestamp":1776232800541}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"NUZ.AU\",,,,,undefined,":{"symbol":"NUZ.AU","floatShares":351374969,"roa":"-60.21%","roe":"-147.09%","lyrEps":-0.034045,"volumeRatio":1.0746772728063376,"shares":708128681,"dividePrice":0,"high":0.09,"amplitude":0.073171,"preClose":0.082,"low":0.084,"week52Low":0.075,"pbRate":"7.61","psRate":"10.54","week52High":0.185,"institutionHeld":0,"latestPrice":0.089,"eps":-0.029543,"divideRate":0,"volume":241840,"delay":0,"ttmEps":-0.029543,"open":0.084,"prevYearClose":0.085,"prevWeekClose":0.083,"prevMonthClose":0.075,"prevQuarterClose":0.075,"fiveDayClose":0.082,"twentyDayClose":0.08,"sixtyDayClose":0.082,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NUZ.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NUZ.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NUZ.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2593925459","title":"BUZZ-Australia's Neurizon Therapeutics drops to 2-year low on discounted placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2593925459","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593925459?lang=en_us&edition=fundamental","pubTime":"2025-12-23 08:03","pubTimestamp":1766448209,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neurizon Therapeutics drops to 2-year low on discounted placement** Shares of Australia's Neurizon Therapeutics NUZ.AX slump as much as 23.6% to A$0.084, their lowest since late Novem","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nL6N3XT000:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593455719","title":"Neurizon Therapeutics Ltd -  Firm Commitments to Raise a$7.1 Mln via Placement at a$0.08 per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2593455719","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593455719?lang=en_us&edition=fundamental","pubTime":"2025-12-23 06:50","pubTimestamp":1766443838,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251222:nFWN3XS0TA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592972182","title":"BRIEF-Neurizon Therapeutics Seeks Trading Halt","url":"https://stock-news.laohu8.com/highlight/detail?id=2592972182","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592972182?lang=en_us&edition=fundamental","pubTime":"2025-12-19 06:14","pubTimestamp":1766096080,"startTime":"0","endTime":"0","summary":"BRIEF-Neurizon Therapeutics Seeks Trading Halt Dec 19 (Reuters) - Neurizon Therapeutics Ltd NUZ.AX:SEEKS TRADING HALT PENDING PROPOSED CAPITAL RAISING ANNOUNCEMENTFurther company coverage: NUZ.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO13K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592182944","title":"Neurizon Therapeutics - Seeks Trading Halt Pending Proposed Capital Raising Announcement","url":"https://stock-news.laohu8.com/highlight/detail?id=2592182944","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592182944?lang=en_us&edition=fundamental","pubTime":"2025-12-19 06:14","pubTimestamp":1766096047,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nFWN3XO13K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590422573","title":"ASX Penny Stocks To Consider In December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2590422573","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590422573?lang=en_us&edition=fundamental","pubTime":"2025-12-12 10:05","pubTimestamp":1765505127,"startTime":"0","endTime":"0","summary":"As the Australian market shows signs of a potential rally to close out the year, investors are eyeing opportunities that extend beyond the major indices. Penny stocks, often associated with smaller or newer companies, continue to attract attention for their potential growth and value propositions. Despite being considered an outdated term by some, these stocks remain relevant as they can offer unique opportunities for those looking to explore under-the-radar investments with strong financial...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nuz/neurizon-therapeutics-shares/news/asx-penny-stocks-to-consider-in-december-2025-1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nuz/neurizon-therapeutics-shares/news/asx-penny-stocks-to-consider-in-december-2025-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MTO.AU","BK7050","DXB.AU","BK7128","AAL.AU","IGL.AU","BK7077","BK7506","BK7055","BK7096","BK7507","NUZ.AU","BK7104","BK7048","BK7067","EDU.AU","BK7111","BK7095","BK7012","BK7045","MLX.AU","WAF.AU","BK7132","DSK.AU","BK7501","SSM.AU","VRS.AU","BK7143","BK7508","GWA.AU","EZZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590493895","title":"FDA Clears Nuz-001 for Entry Into Healey ALS Platform Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590493895","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590493895?lang=en_us&edition=fundamental","pubTime":"2025-12-12 04:50","pubTimestamp":1765486245,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nFWN3XH1E2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590698455","title":"Neurizon Says US FDA Clears Use of Drug Candidate in ALS Clinical Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2590698455","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590698455?lang=en_us&edition=fundamental","pubTime":"2025-12-11 12:19","pubTimestamp":1765426747,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  said that the Sean M. Healey & AMG Center for ALS at Mass General Brigham in Massachusetts received clearance from the US Food and Drug Administration to proceed with the NUZ-001 regimen, Neurizon's drug candidate for the treatment of amyotrophic lateral sclerosis , in the Healey ALS Platform trial after the regulator completed a 30-day review, according to a Thursday Australian bourse filing.The US FDA's acceptance of the protocol amendment allows the firm and the clinical trial team to progress to the next operational phases, including submissions to the Institutional Review Board, activation of clinical trial sites, and initiation of study start-up activities.The trial tests and evaluates multiple investigational drugs simultaneously, sharing infrastructure across trial sites.The first patients are expected to be enrolled early in 2026, the filing said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2590568384","title":"BUZZ-Australia's Neurizon Therapeutics jumps after US FDA clears ALS product for trial use","url":"https://stock-news.laohu8.com/highlight/detail?id=2590568384","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590568384?lang=en_us&edition=fundamental","pubTime":"2025-12-11 10:13","pubTimestamp":1765419221,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neurizon Therapeutics jumps after US FDA clears ALS product for trial use** Shares of Australia's Neurizon Therapeutics NUZ.AX jump as much as 8.7% to A$0.125, their highest since November 20** Neurodegenerative disease-focused biotech co says the U.S. Food and Drug Administration has cleared the use of its \"NUZ001 regimen\" in the HEALEY ALS platform trial** NUZ-001 is a potential treatment option for people living with amyotrophic lateral sclerosis , a progressive neurodegenerative disorder     ** YTD, shares down 32.4%  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251211:nL6N3XH050:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588079530","title":"Neurizon Completes Manufacturing Three Registration Batches of Drug Candidate to Treat Neurodegenerative Disease; Shares Fall 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588079530","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588079530?lang=en_us&edition=fundamental","pubTime":"2025-12-04 09:42","pubTimestamp":1764812538,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics  has completed the manufacturing of three planned registration batches of its NUZ-001 tablets for the treatment of Amyotrophic Lateral Sclerosis , according to a Thursday filing with the Australian bourse.The company can now pursue a Rolling Review of the New Drug Application , allowing the US Food and Drug Administration to review chemistry, manufacturing, and controls details before the full NDA submission, the filing said.The batches have been placed on both long-term and accelerated stability programs to establish product shelf-life, the filing added.Neurizon said it is on track to start patient enrolment in the HEALEY ALS platform trial in the first quarter of 2026, the company said.Shares of the company fell 5% in recent Thursday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586296817","title":"Elanco Executive Justine Conway Appointed as Neurizon Therapeutics Board Observer","url":"https://stock-news.laohu8.com/highlight/detail?id=2586296817","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586296817?lang=en_us&edition=fundamental","pubTime":"2025-11-27 07:17","pubTimestamp":1764199037,"startTime":"0","endTime":"0","summary":"Neurizon Therapeutics Ltd. has appointed Justine Conway, Global Head of Business Development at Elanco Animal Health, as a Board Observer. Conway will participate in Neurizon's Board and committee meetings as Elanco's designated representative, bringing extensive experience in business development and strategic partnerships to the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurizon Therapeutics Ltd. published the original content used to generate this news brief via PR Newswire  on November 26, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDL5C3NYq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELAN","LU1941712348.USD","LU1941712264.USD","BK4561","BK7096","BK4007","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586329681","title":"Elanco Executive Appointed as Neurizon's Board Observer","url":"https://stock-news.laohu8.com/highlight/detail?id=2586329681","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586329681?lang=en_us&edition=fundamental","pubTime":"2025-11-27 07:16","pubTimestamp":1764198985,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nTUA2494QB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2586296810","title":"Press Release: Elanco executive appointed as Neurizon's Board Observer","url":"https://stock-news.laohu8.com/highlight/detail?id=2586296810","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586296810?lang=en_us&edition=fundamental","pubTime":"2025-11-27 07:16","pubTimestamp":1764198960,"startTime":"0","endTime":"0","summary":"MELBOURNE, Australia, Nov. 26, 2025 /PRNewswire/ -- Neurizon Therapeutics Limited  , a clinical-stage biotech company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to announce the appointment of Ms Justine Conway as a Board Observer. Ms Conway currently serves as Global Head of Business Development at Elanco Animal Health   and will participate in Neurizon's Board activities as Elanco's designated representative.The appointment highlights the strength of Neurizon's relationship with Elanco, as well as Elanco's ongoing partnership with Neurizon. The appointment follows an exclusive global license agreement for Monepantel, the active pharmaceutical ingredient in NUZ-001 . This agreement marks a major milestone for Neurizon and supports the Company's regulatory foundations, providing ongoing access to critical animal safety data and manufacturing data, key pillars required to support future clinical trials, potential regulatory approvals and globa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELAN","BK4561","BK7096","R","BK4232","LU1941712264.USD","NUZ.AU","BK4007","LU1941712348.USD","NUZTF","BK4022"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2579891654","title":"Neurizon Therapeutics Ltd-Appendix 4C & Quarterly Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2579891654","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579891654?lang=en_us&edition=fundamental","pubTime":"2025-10-29 06:43","pubTimestamp":1761691388,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nTUE8R3HGS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2578690735","title":"Notice of Annual General Meeting & Proxy Form-GDR","url":"https://stock-news.laohu8.com/highlight/detail?id=2578690735","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578690735?lang=en_us&edition=fundamental","pubTime":"2025-10-27 15:40","pubTimestamp":1761550836,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251027:nASX9X0M4m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nASX4DFtk7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2578901616","title":"Pre-Quotation Disclosure-GDR","url":"https://stock-news.laohu8.com/highlight/detail?id=2578901616","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578901616?lang=en_us&edition=fundamental","pubTime":"2025-10-27 15:36","pubTimestamp":1761550595,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251027:nASX44pFcv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nASXKKDnY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2578669096","title":"Corporate Governance Statement-GDR","url":"https://stock-news.laohu8.com/highlight/detail?id=2578669096","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578669096?lang=en_us&edition=fundamental","pubTime":"2025-10-27 15:32","pubTimestamp":1761550348,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251027:nASX13Bdg2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nASX4nSgD0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2578069038","title":"Top 20 Shareholders-GDR","url":"https://stock-news.laohu8.com/highlight/detail?id=2578069038","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578069038?lang=en_us&edition=fundamental","pubTime":"2025-10-27 15:23","pubTimestamp":1761549814,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251027:nASX7779vt","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nASX5cwsVv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2578697852","title":"Neurizon Therapeutics Ltd-Distribution Schedule-Gdr","url":"https://stock-news.laohu8.com/highlight/detail?id=2578697852","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578697852?lang=en_us&edition=fundamental","pubTime":"2025-10-27 15:22","pubTimestamp":1761549733,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nTUE9GB8YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2578690813","title":"Distribution Schedule-GDR","url":"https://stock-news.laohu8.com/highlight/detail?id=2578690813","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578690813?lang=en_us&edition=fundamental","pubTime":"2025-10-27 15:22","pubTimestamp":1761549733,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251027:nASX8RCyMD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nASX7k9Xmq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NUZ.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2578697763","title":"Securities Trading Policy-GDR","url":"https://stock-news.laohu8.com/highlight/detail?id=2578697763","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578697763?lang=en_us&edition=fundamental","pubTime":"2025-10-27 15:16","pubTimestamp":1761549382,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251027:nASX2wd2by","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nASX71hzHC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUZ.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":49,"code":"91000000","status":"200"}]}}